179
Views
5
CrossRef citations to date
0
Altmetric
Review

Pre-exposure prophylaxis for sexually-acquired HIV risk management: a review

, , &
Pages 125-136 | Published online: 28 Apr 2015

Abstract

Despite significant efforts, the rate of new HIV infections worldwide remains unacceptably high, highlighting the need for new HIV prevention strategies. HIV pre-exposure prophylaxis (PrEP) is a new approach that involves the ongoing use of antiretroviral medications by HIV-negative individuals to reduce the risk of HIV infection. The use of daily tenofovir/emtricitabine as oral PrEP was found to be effective in multiple placebo-controlled clinical trials and approved by the United States Food and Drug Administration. In addition, the Centers for Disease Control and Prevention in the United States and the World Health Organization have both released guidelines recommending the offer of oral PrEP to high-risk populations. The scale-up of PrEP is underway, but several implementation questions remain unanswered. Demonstration projects and open-label extensions of placebo-controlled trials are ongoing and hope to contribute to our understanding of PrEP use and delivery outside the randomized controlled trial setting. Evidence is beginning to emerge from these open-label studies and will be critical for guiding PrEP scale-up. Outside of such studies, PrEP uptake has been slow and several client- and provider-related barriers are limiting uptake. Maximizing the public health impact of PrEP will require rollout to be combined with interventions to promote uptake, support adherence, and prevent increases in risk behavior. Additional PrEP strategies are currently under investigation in placebo-controlled clinical trials and may be available in the future.

Introduction

Despite significant efforts, the rate of new HIV infections worldwide remains unacceptably high. According to the Joint United Nations Programme on HIV/AIDS (UNAIDS), there were an estimated 2.1 million new HIV infections in 2013Citation1 and country-level surveillance suggests that HIV incidence is rising among certain populations, such as among men who have sex with men (MSM) in North America, Western Europe, and Australia,Citation2 and people who inject drugs (PWID) in Central Asia.Citation3 This continuing epidemic highlights the urgent need for new HIV prevention strategies.

HIV pre-exposure prophylaxis (PrEP) involves the ongoing use of antiretroviral medications by HIV-negative individuals to reduce the risk of HIV infection. This prevention approach was found to be effective in multiple randomized, placebo-controlled, double-blinded clinical trials (RCTs). Within the past 3 years, the United States Food and Drug Administration (FDA) has approved tenofovir (TDF) plus emtricitabine (FTC) for use as oral PrEP and the US Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) have both released guidelines recommending the offer of oral PrEP to individuals at high risk of HIV infection.Citation4,Citation5 Open-label extensions (OLEs) of PrEP RCTs and demonstration projects are currently underway in several countries to evaluate “real-world” implementation issues. This paper discusses the current and future state of PrEP science and implementation.

Interpreting RCT evidence on PrEP efficacy and safety

Efficacy

Several RCTs have found that the use of a daily pill containing TDF alone, or in combination with FTC, can reduce the risk of HIV transmission in key populations, including heterosexual serodiscordant couples, sexually active heterosexual men and women, MSM, and PWID.Citation6Citation11 While the RCT demonstrating effectiveness among MSM also included transgender women who have sex with men, they represented a minority (1.2%) of participants enrolled.Citation6

In these RCTs, the overall reduction in HIV risk provided by oral PrEP ranged from 0%–75% (). There is a general consensus that different levels of adherence among participants are responsible for this wide range in efficacy estimates.Citation12 While adherence to daily pill-taking, according to self-report and pill counts, in all clinical trials was high (84%–95%), the proportion of participants in the PrEP arms with detectable serum drug levels was lower and ranged from 24%–82%. In the two studies where the proportion with detectable drug levels was 30% or less, there was no statistically significant difference in HIV incidence between the PrEP and placebo arms.Citation10,Citation11 Both of these trials (FEM-PrEPCitation10 and VOICECitation11) enrolled high-risk heterosexual women in sub-Saharan Africa, raising initial concerns that PrEP may not work for women. However, TDF-based oral PrEP was effective for women in the Partners PrEP and TDF2 studies.Citation7,Citation8 Factors other than adherence, such as mucosal inflammation or differential drug penetration in the female genital tract, may have partially contributed to the lack of efficacy in the FEM-PrEP and VOICE studies.Citation12

Table 1 Summary of completed PrEP RCTs

PrEP efficacy was higher among participants who adhered more consistently to daily pill-taking, as determined by self-report, pill counts, and drug levels. In two nested case-control analyses, the risk of HIV infection was between 86%–92% lower among those with detectable drug in their blood when compared to those without.Citation6,Citation13 Drug levels equivalent to taking TDF/FTC daily were associated with a 99% reduction in HIV risk in a pharmacokinetic-based modeling study.Citation14 Interestingly, this pharmacokinetic model demonstrated a PrEP efficacy of 96% with four doses per week, suggesting intermittent strategies may be a viable option. Indeed, an RCT investigating intermittent TDF/FTC was recently stopped early due to high efficacy.Citation15

Topical PrEP strategies have been evaluated in two clinical trials. In the CAPRISA 004 study,Citation16 a TDF-based vaginal gel, applied before and after sex, reduced the overall risk of HIV infection among high-risk women in South Africa by 39%. The reduction in HIV risk was 74% among women who used the gel more consistently.Citation17 The daily use of this TDF-based vaginal gel did not protect female study participants in the VOICE study,Citation11 most likely due to low adherence.

Safety

TDF-based oral PrEP appears to be generally safe and well tolerated. This type of PrEP did not increase rates of serious (grade 3 or 4) adverse events in any studies. In some trials, oral PrEP did increase the risk of nausea, vomiting, diarrhea, unexplained weight loss, fatigue, and dizziness compared to placebo.Citation6Citation11 However, side effects were generally mild, infrequent (affected 1%–10% of participants), and disappeared after 1 month or 2 months of use. Babies born to women who became pregnant while taking oral PrEP in the Partners PrEP studyCitation18 did not appear to have negative health outcomes. However, women discontinued PrEP when pregnancy was detected, which may have limited potential toxicity. The use of a TDF vaginal gel before and after sex was associated with a small increase in mild, self-limited diarrhea.Citation16

PrEP has been associated with other, potentially more serious toxicities. TDF-based oral PrEP can cause small but statistically significant decreases in kidneyCitation19,Citation20 and liver functionCitation9,Citation10 and bone mineral density (BMD).Citation21,Citation22 Promisingly, renal function tended to return to normal after discontinuation of PrEP and decreases in BMD did not increase the risk of fracture. However, the long-term clinical significance of these changes remains unclear, as most trials only followed participants for a median of 1–2 years.

Development of drug resistance is a concern for individuals who use PrEP while unknowingly infected with HIV, because HIV treatment generally requires three antiretroviral drugs to fully suppress viremia. Fortunately, drug resistance was relatively rare among PrEP users who were HIV-negative at enrolment and became infected during follow up (0%–12% of incident cases).Citation6,Citation8,Citation12,Citation23Citation25 However, resistance was frequently observed in participants who started PrEP when they were already infected (up to 100% of such cases). These individuals were likely in the acute stage of HIV infection at enrolment, as their infection was missed by antibody tests used at baseline to determine study eligibility. The high viral load during this stage may create optimal conditions for development of resistance. Promisingly, levels of drug-resistant virus in those initiating PrEP during acute HIV infection in the iPrEX studyCitation25 decreased to low background levels 24 weeks after PrEP was discontinued. As such, the impact of PrEP-related drug resistance on future treatment options is unclear.

Importantly, clinical trials may have underestimated the rate of side effects, toxicities, and drug resistance due to low adherence among study participants. Furthermore, clinical trials had strict eligibility criteria and only enrolled generally healthy individuals. Therefore, the safety of PrEP when used by individuals with underlying health conditions is not known. What is evident, however, is the importance of baseline assessment and ongoing monitoring of HIV status, BMD, renal and liver function, and pregnancy. Ruling out acute HIV infection prior to PrEP initiation is critical, by screening for acute HIV symptoms and by using testing technologies with shorter window periods, such as nucleic acid amplification tests and antigen/antibody combination tests.

Translating PrEP into a reduction in HIV incidence in the “real world”: challenges and opportunities

Evidence of safety and reduced HIV risk at the individual level (ie, efficacy) from RCTs has led the WHO and CDC to recognize PrEP as an important component of a comprehensive approach to HIV prevention.Citation4,Citation5 PrEP scale-up is thus underway, but several implementation questions remain unanswered. For instance, the extent to which PrEP can contribute to reductions in HIV incidence outside of clinical trial settings (ie, effectiveness) is unknown. Modeling studies suggest that the public health impact of PrEP could be limited by slow uptake, poor adherence, and increases in risk behavior (risk compensation).Citation26 To address these issues, more than 20 demonstration projects and OLEs of PrEP RCTs are currently planned or ongoing and will contribute to our understanding of PrEP use and delivery outside the RCT setting ().

Table 2 Summary of planned and ongoing demonstration projects evaluating “open label” use of daily oral TDF/FTC

Uptake and hypothetical acceptability

Overall, PrEP uptake among at-risk populations has been slow in the US, the country where the most progress has been made to move PrEP into practice. While surveys generally suggest that willingness to use PrEP among MSM (the population most affected by HIV in the US) is moderate to high, the proportion reporting PrEP use has not exceeded 5% in any of these early studies.Citation27Citation32 Similar levels of hypothetical acceptability have been observed in MSM in other countries,Citation27,Citation28,Citation33Citation35 as well as in sex workers,Citation27,Citation36 PWID,Citation37 and women.Citation38,Citation39 However, populations other than MSM in the US remain understudied.

The most comprehensive study of PrEP uptake to date was based on prescription data from 55% of the retail pharmacies across the US; it determined that 3,253 individuals started PrEP between January 2012 and April 2014.Citation40 While this study did not capture individuals accessing PrEP through demonstration projects or OLEs, the total number of PrEP users in the US at that time was undoubtedly much lower than the 500,000 that the CDC estimates would benefit from this strategy.Citation41 The discordance between high hypothetical acceptability and low actual use suggest that barriers to PrEP uptake exist.

Potential client-related barriers to uptake

Uptake of PrEP can be initiated by a client or a provider, but several individual- and structural-level barriers may limit both. A major barrier to client-initiated PrEP (self-referral) is the lack of awareness among those at risk.Citation27,Citation28 Among individuals who are aware of PrEP and are interested in using it, a lack of access to a health care provider or a lack of comfort talking to a provider about PrEP may present additional barriers.Citation30,Citation32 In a recent survey of over 9,000 MSM in the US, 16% did not have a primary care provider (PCP), and only half of those with a provider felt comfortable talking to them about sex.Citation32 Race-based medical distrust has been identified as a barrier to PrEP use among black MSM in the US.Citation30

The high cost of PrEP is undoubtedly a major barrier to uptake worldwide, particularly in high-income countries where only branded TDF/FTC is available. In the US, financial coverage through private health insurance appears to be widespread, and Gilead Sciences has developed a financial assistance program for individuals without insurance. The extent of financial coverage in other countries is unclear.

Potential provider-related barriers to uptake

Provider-level barriers include a lack of PrEP awareness and knowledge, as well as negative opinions and attitudes toward PrEP. These barriers may deter service providers from recommending or prescribing PrEP to those who may benefit. Surveys of physicians in North America generally suggest that awareness, support, and willingness to prescribe are moderate to high.Citation42Citation49 However, some surveys were biased by the high proportion of providers with experience working in HIV and, indeed, familiarity with HIV and PrEP has been associated with willingness to prescribe.Citation43,Citation48 Other potential barriers to prescribing include concerns about cost, safety, efficacy, risk compensation, adherence, time commitment, and a lack of guidelines.Citation42Citation49

Confusion exists as to which health care providers are best suited to prescribe PrEP. While HIV specialists may have the most experience prescribing antiretrovirals, PCPs are more likely to have contact with uninfected, high-risk populations.Citation50 In a Boston-based study,Citation50 HIV care providers indicated that PrEP delivery would be more feasible in primary care clinics. In another US study, willingness to prescribe PrEP among PCPs was between 20%–45%, and this was associated with self-efficacy (ie, perceived ability to identify at-risk individuals, prescribe PrEP, and support PrEP users).Citation46 This finding emphasizes the need for interventions to increase physician comfort and confidence in prescribing PrEP. Arguments have also been advanced to involve other health care providers in PrEP prescribing and monitoring, such as pharmacists and nurses, potentially increasing capacity and limiting costs.Citation51

Nonprescribing service providers, such as staff at HIV testing sites and AIDS service organizations (ASOs), also have an important role to play in the implementation of PrEP.Citation52 These organizations have regular contact with people at high risk of HIV infection and are in an ideal position to educate and link clients to locations where it is available. Similar to health care providers, a lack of awareness and negative PrEP attitudes among nonprescribing service providers may limit uptake. However, few studies have focused on these providers. In a Canadian survey of ASO staff, almost half (49%) supported regulatory approval of PrEP, 26% had been asked about PrEP, but the majority (61%) felt that they did not have enough PrEP knowledge.Citation53 More research is needed to understand the opinions of nonclinical providers and explore their role in PrEP implementation within the context of increasing medicalization of HIV prevention.Citation54

“Real-world” barriers to uptake and emerging data from demonstration projects and OLEs

Few empirical studies have assessed “real-world” barriers to PrEP uptake. While client and provider education, PrEP referrals and linkage, and willingness to prescribe are important, one study found that they may not be sufficient to maximize uptake.Citation55 In this study, “high risk” MSM presenting at HIV testing sites in San Diego, CA, USA from May 2012 to October 2012 were educated about PrEP and asked if they would consent to a referral to a clinic willing to prescribe PrEP at-cost.Citation55 Referrals were offered to 416 men, but only 14 consented and even fewer (number [n] =2) started PrEP. The most common reasons for not consenting to referral were low perceived risk of HIV infection (30%) and concerns about cost (48%), long-term side effects (41%), and taking daily medications (30%). The two individuals who started PrEP covered the cost through their private health insurance.

Information emerging from demonstration projects and OLEs (where PrEP is offered free of charge by knowledgeable providers) suggests that uptake can be high in settings where cost and provider-related barriers have been removed. Settings explored in these open-label studies include a community health center, sexually transmitted disease (STD) clinics, and a private health organization in the US;Citation56,Citation57 reproductive health programs in high-income countries;Citation56,Citation58,Citation59 genitourinary medicine clinics in the United Kingdom;Citation60 prevention services for heterosexual serodiscordant couples in Eastern Africa;Citation61 and the TDF2, iPrEX, and Partners PrEP OLEs.Citation62Citation64 For example, the US Demonstration Project has integrated PrEP into STD clinics in San Francisco, CA, USA and Miami, FL, USA, and into a community health center in Washington, DC, USA.Citation56,Citation57 From September 2012 to January 2014, 922 eligible MSM and transgender women were offered PrEP and 557 (60%) initiated it.Citation57 Of note, self-referrals (n=299) and clinic referrals (n=258) differed in terms of several socio-demographic characteristics, emphasizing the importance of promoting both in order to reach a wide range of at-risk individuals. The high acceptability in the OLEs is particularly reassuring as these individuals have already experienced several months of daily pill-taking and quarterly study visits. The most common client-related barriers to uptake among MSM in the iPrEX OLE and US Demonstration Project were low perceived risk of HIV infection, concerns about safety, and not wanting to take a pill every day.Citation56,Citation57,Citation63

PrEP-related stigma has also emerged as a particularly concerning issue. In one demonstration project, the social harm most commonly reported by MSM was stigma from peers and health care providers as a result of their PrEP use.Citation56 This stigma has also emerged in the media, with a Huffington Post article denouncing PrEP users as “Truvada Whores”.Citation65 Some PrEP users have reappropriated this term by posting images on social media sites of themselves wearing “#TruvadaWhore” T-shirts (). This sex-negative and judgmental reaction to PrEP draws parallels to the emergence of oral contraceptive pills in the 1960s, which are now widely accepted.Citation66

Figure 1 Truvadawhore T-shirt.

Figure 1 Truvadawhore T-shirt.

Improving access and increasing uptake

Increasing the awareness and knowledge of PrEP’s proven efficacy and safety among at-risk populations and service providers will be an important first step to maximizing its appropriate uptake. Application of diffusion of innovation theory and lessons learned from the health communication field may be useful in designing interventions to increase uptake.Citation67 Research is needed to understand how PrEP messaging affects uptake and how social and sexual networks can facilitate awareness and self-referrals for PrEP.Citation68,Citation69 Promoting PrEP as a healthy, responsible choice may help decrease stigma and increase uptake.

Other important interventions include those to bridge the disconnect between subjective and objective perceptions of HIV risk,Citation70 empower individuals to self-advocate and self-refer, and facilitate financial coverage. In countries outside the US, regulatory approval and provider guidelines may help improve awareness, increase provider comfort in recommending/prescribing PrEP appropriately, and pave the way to wider financial coverage through public and private health insurance.

Prioritizing PrEP uptake

The public health impact of PrEP not only depends on how many people use it, but also who uses it. HIV risk within higher incidence populations is not uniform, and prioritizing PrEP uptake among those at highest risk is important to maximize its overall impact and cost-effectiveness.Citation26 Promisingly, higher-risk sexual behaviors (as determined by self-report and the presence of sexually transmitted infections [STIs]) were associated with PrEP uptake among MSM in the iPrEX OLE.Citation63

An important challenge is therefore finding ways to identify those individuals at highest risk. Service providers, particularly physicians, often have difficulty assessing HIV risk.Citation71 For instance, surveys suggest that health care providers would prioritize serodiscordant couples for PrEP,Citation46,Citation49,Citation72 but because treatment of the HIV-infected partner in such relationships is already associated with a 96% reduction in transmission risk,Citation73 or perhaps more,Citation74 PrEP may be of limited incremental value in this scenario. Indeed, research suggests most HIV transmissions originate from those who are unaware of their HIV status and a minority originate from those aware of their status, particularly if they are on treatment.Citation75,Citation76

Tools are needed to help providers identify those who may benefit most from PrEP. HIV risk criteria for determining PrEP eligibility in many guidelines and open-label studies are broad and nonspecific.Citation77 Clinical HIV risk scoring tools may be useful to help screen individuals for PrEP eligibility and have been developed for MSM in the USCitation78 and heterosexual serodiscordant couples in sub-Saharan Africa.Citation79 Analyses of HIV risk factors in PrEP RCTs have also provided important insight into who should be prioritized for PrEP. A secondary analysis of the iPrEX trial found that the number needed to treat (NNT) was 62 overall and would be lowest if PrEP was targeted to MSM reporting cocaine use (NNT =12), an STI (NNT =41), or condomless receptive anal sex with unknown status partners (NNT =41), partners known to be HIV-positive (NNT =24), or only partners believed to be HIV-negative (NNT =15).Citation80 A separate analysis identified syphilis as an important predictor of incident HIV infection in the iPrEX study.Citation81 These findings highlight the importance of provider-initiated discussions with clients on sexual behavior, partner HIV status, substance use, and STI history in order to assess PrEP eligibility.

Adherence

Adherence is critical to reduce HIV incidence among those who initiate PrEP. In PrEP RCTs, adherence was generally low and several factors were associated with poor compliance, such as substance use, a lack of partner support, longer time in study, ambivalence toward research, knowing the pill was investigational and may not work, stigma, low perceived risk of HIV infection, and lower-risk sexual activity.Citation82Citation84 The most consistent factor associated with lower adherence across RCTs was younger age.Citation82

Little information is available on PrEP adherence outside RCT settings, but some findings are beginning to emerge from demonstration projects and OLEs. These findings suggest adherence may be higher in open-label settings (where a person knows the pill they are taking is effective against HIV transmission), but it will likely remain a challenge for some individuals. In the iPrEX OLE,Citation63 there was evidence that adherence was higher when compared to the RCT phase of the study, but overall adherence was low. Drug levels equivalent to 4–7 pills a week were only present at 33% of study visits and most HIV infections occurred during gaps in PrEP use. Adherence was high at the beginning of the study, but it decreased over the 72-week follow up, suggesting the need for intensified interventions as time on PrEP increases. At week 4 in the US Demonstration Project, 77% of participants had drug concentrations consistent with taking at least four pills a week, but a smaller proportion (between 14%–52%, depending on the study site) were taking pills every day.Citation57 Early discontinuation of the deferred arm in the PROUD demonstration projectCitation85 (due to high efficacy - 86%) suggests that adherence in the PrEP arm was high.Citation86

People at risk of HIV infection go through periods of higher and lower risk.Citation87 Greater adherence during higher-risk periods is important to maximize the effectiveness of PrEP. Unfortunately, factors that put someone at higher risk may be the same that compromise adherence (eg, substance use, mental health issues). Promisingly, in the iPrEX OLE, higher drug concentrations were associated with self-reported HIV risk behaviors, such as condomless receptive anal sex, more sexual partners, having an HIV-positive sexual partner, and having a history of STIs.Citation63 Use of drugs and alcohol were not associated with adherence. Ongoing HIV risk assessments of PrEP users may be important for informing uptake and intensifying adherence interventions during periods of higher risk.

PrEP rollout needs to be combined with interventions to support daily pill-taking and engagement in PrEP services. Currently, no evidence-based strategy is available to support open-label PrEP use, although several strategies were found to be effective/acceptable in other prevention fieldsCitation88 and in PrEP RCTs.Citation89Citation91 Ongoing and planned demonstration projects and OLEs are evaluating several types of approaches ().

Risk behavior and risk compensation

Increases in risk behavior as a result of PrEP use may offset the impact of this strategy on HIV incidence and increase the rates of other STIs. Similar to adherence, most information on risk compensation comes from RCTs. In these studies, self-reported risk behaviors declined, perhaps the result of ongoing risk-reduction services provided to participants.Citation92Citation94 While social desirability bias may partly explain decreases in self-reported HIV risk behaviors, rates of HIV and syphilis infections (objective measures of risk behaviors) also decreased during follow up in the iPrEX RCT.Citation92

Risk compensation may be more likely during open-label use, where a PrEP user knows for certain that the pill he or she is taking is effective. However, the limited available evidence suggests this is not the case. In the Partners PrEP OLE,Citation95 unprotected sex acts within the main partnership decreased when compared to the RCT phase, and rates of STIs and pregnancy did not increase. There was, however, a small increase in unprotected sex acts with outside partners. In the iPrEX OLE,Citation63 self-reported risk behaviors decreased over the duration of the study, and the incidence of syphilis was similar among those taking PrEP and those who were not. These findings suggest that risk compensation is not a concern when PrEP is used by people who are already engaging in higher-risk behaviors and when regular risk-reduction services are provided. Combining PrEP rollout with evidence-based HIV risk-reduction approaches,Citation96,Citation97 as well as baseline/ongoing HIV risk assessments to determine PrEP eligibility, may limit the potential for risk compensation.

Additional benefits of PrEP

PrEP can provide benefits that go beyond its direct effect on HIV risk, as it offers an opportunity to engage high-risk individuals in services that they otherwise may not access. This includes services that are part of the standard PrEP package, such as regular HIV and STI testing, medical checkups, and risk-reduction services. These services can facilitate earlier identification of health conditions (eg, HIV and STIs) or vulnerabilities (eg, hepatitis B virus susceptibility) and provide an opportunity to (re)engage individuals in care, treatment, and prevention services. This may help improve health and prevent the secondary transmission of STIs and HIV. Interestingly, PrEP may also have a direct effect on STI incidence, as some research suggests that daily TDF/FTC reduces herpes simplex virus 2 and hepatitis B virus acquisition,Citation98,Citation99 as well as the occurrence of ulcers among those already infected with herpes simplex virus.Citation100

PrEP also offers the opportunity to link high-risk individuals to other services to promote health and address an individual’s underlying risk of HIV infection. Insight from postexposure prophylaxis (PEP) programs shows that MSM accessing this biomedical intervention tend to have a high prevalence of coexisting health problems, such as depression and substance use, which are “syndemic” and can reinforce HIV risk.Citation101 Unfortunately, PEP access is rarely used to leverage additional services and, as a result, HIV risk often remains high after PEP is completed.Citation102 Combining PEP and PrEP with routine screening for these health issues, and linkage to relevant services, will thus be important. Research also suggests that PrEP can have a positive and direct impact on mental health by decreasing some of the anxiety, guilt, and fear associated with “risky sex” and becoming infected with HIV.Citation103

The future state of PrEP

While PrEP is currently synonymous with the use of daily TDF/FTC pills, this may not always be the case. Intermittent use of TDF/FTC has been found to be effective in the placebo-controlled IPERGAY trial.Citation11 Further PrEP strategies under investigation include TDF-based vaginal and rectal gels, long-lasting rilpivirine injections, and slow-release dapivirine intravaginal rings. Many of these strategies have the potential to reduce costs, side effects, and barriers to adherence.

Conclusion

PrEP is an exciting new addition to the armamentarium of biomedical and behavioral approaches to HIV prevention. However, important knowledge gaps remain and there has been limited open-label experience with PrEP. Data are beginning to emerge from demonstration projects and OLEs, and this information will be critical to guiding PrEP scale-up in different populations and geographic settings. As usage becomes more routine, close surveillance will be required to capture rare events and unintended consequences. Finally, as the toolkit of prevention strategies expands, there will be an increasing need for program science approaches evaluating PrEP as part of a broader suite of complex HIV prevention interventions.

Disclosure

DHST has received honoraria from Abbvie, Bristol Myers Squibb, Gilead, Janssen, Merck, and Viiv, and holds research grants from Gilead and Viiv. The other authors report no conflicts of interest in this work.

References

  • UNAIDSThe Gap ReportGeneva, SwitzerlandUNAIDS2014 Available from: http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Gap_report_en.pdfAccessed December 23, 2014
  • BeyrerCBaralSDvan GriensvenFGlobal epidemiology of HIV infection in men who have sex with menLancet2012380983936737722819660
  • El-BasselNStrathdeeSAEl SadrWMHIV and people who use drugs in central Asia: confronting the perfect stormDrug Alcohol Depend2013132Suppl 1S2S623953656
  • US Public Health ServicePreexposure Prophylaxis for the Prevention of HIV Infection in the United States – 2014: A Clinical Practice GuidelineAtlanta, GACenters for Disease Control and Prevention2014 Available from: http://www.cdc.gov/hiv/pdf/prepguidelines2014.pdfAccessed December 23, 2014
  • World Health OrganizationConsolidated Guidelines on HIV Prevention, Diagnosis, Treatment and Care for Key PopulationsGeneva, SwitzerlandWorld Health Organization2014 Available from: http://apps.who.int/iris/bitstream/10665/128048/1/9789241507431_eng.pdf?ua=1&ua=1Accessed December 23, 2014
  • GrantRMLamaJRAndersonPLiPrEx Study TeamPreexposure chemoprophylaxis for HIV prevention in men who have sex with menN Engl J Med2010363272587259921091279
  • BaetenJMDonnellDNdasePPartners PrEP Study TeamAntiretroviral prophylaxis for HIV prevention in heterosexual men and womenN Engl J Med2012367539941022784037
  • ThigpenMCKebaabetswePMPaxtonLATDF2 Study GroupAntiretroviral preexposure prophylaxis for heterosexual HIV transmission in BotswanaN Engl J Med2012367542343422784038
  • ChoopanyaKMartinMSuntharasamaiPBangkok Tenofovir Study GroupAntiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trialLancet201338198832083209023769234
  • Van DammeLCorneliAAhmedKFEM-PrEP Study GroupPreexposure prophylaxis for HIV infection among African womenN Engl J Med2012367541142222784040
  • MarrazzoJMRamjeeGRichardsonBATenofovir-based preexposure prophylaxis for HIV infection among African womenNew Engl J Med2015372650951825651245
  • van der StratenAVan DammeLHabererJEBangsbergDRUnraveling the divergent results of pre-exposure prophylaxis trials for HIV preventionAIDS2012267F13F1922333749
  • DonnellDBaetenJMBumpusNNHIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV preventionJ Acquir Immune Defic Syndr201466334034824784763
  • AndersonPLGliddenDVLiuAiPrEx Study TeamEmtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with menSci Transl Med20124151151ra125
  • MolinaJMCapitantCSpireBOn demand PrEP with oral TDF-FTC in MSM: Results of the ANRS Ipergay trialConference on Retroviruses and Opportunistic InfectionsFeb 23–26, 2015Seattle, WA Abstract 23LB
  • Abdool KarimQAbdool KarimSSFrohlichJACAPRISA 004 Trial GroupEffectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in womenScience201032959961168117420643915
  • KarimSSKashubaADWernerLKarimQADrug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in womenLancet2011378978727928121763939
  • MugoNRHongTCelumCPartners PrEP Study TeamPregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trialJAMA2014312436237125038355
  • SolomonMMLamaJRGliddenDViPrEx Study TeamChanges in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxisAIDS201428685185924499951
  • MartinMVanichseniSSuntharasamaiPBangkok Tenofovir Study GroupRenal function of participants in the Bangkok tenofovir study – Thailand, 2005–2012Clin Infect Dis201459571672424829212
  • LiuAYVittinghoffESellmeyerDEBone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San FranciscoPLoS One201168e2368821897852
  • KasondeMNiskaRWRoseCBone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in BotswanaPLoS One201493e9011124625530
  • LehmanDABaetenJMMcCoyCPrEP exposure and the risk of low-frequency drug resistanceAbstract presented at: 21st Conference on Retroviruses and Opportunistic InfectionsMarch 3–6, 2014Boston, MA
  • ParikhUMEskayKAHardestyRLHIV-1 resistance outcomes in seroconverters from MTN 003 (VOICE)Abstract presented at: 21st Conference on Retroviruses and Opportunistic InfectionsMarch 3–6, 2014Boston, MA
  • LieglerTAbdel-MohsenMBentleyLGiPrEx Study TeamHIV-1 drug resistance in the iPrEx preexposure prophylaxis trialJ Infect Dis201421081217122724740633
  • GomezGBBorquezACaseKKWheelockAVassallAHankinsCThe cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studiesPLoS Med2013103e100140123554579
  • YoungIMcDaidLHow acceptable are antiretrovirals for the prevention of sexually transmitted HIV?: A review of research on the acceptability of oral pre-exposure prophylaxis and treatment as preventionAIDS Behav201418219521623897125
  • HoltMHIV pre-exposure prophylaxis and treatment as prevention: a review of awareness and acceptability among men who have sex with men in the Asia-Pacific region of the AmericasSex Health201411216617023866853
  • BauermeisterJAMeanleySPingelESolerJHHarperGWPrEP awareness and perceived barriers among single young men who have sex with menCurr HIV Res201311752052724476355
  • EatonLADriffinDDSmithHConway-WashingtonCWhiteDCherryCPsychosocial factors related to willingness to use pre-exposure prophylaxis for HIV prevention among Black men who have sex with men attending a community eventSex Health201411324425125001553
  • RucinskiKBMensahNPSepkowitzKACutlerBHSweeneyMMMyersJEKnowledge and use of pre-exposure prophylaxis among an online sample of young men who have sex with men in New York CityAIDS Behav20131762180218423479003
  • MayerKHOldenbergKNovakDKrakowerDEarly adopters: correlates of chemoprophylaxis use in an online sample of US men who have sex with menAbstract presented at: 21st Conference on Retroviruses and Opportunistic InfectionsMarch 3–6, 2014Boston, MA
  • LeonardiMLeeETanDHAwareness of, usage of and willingness to use HIV pre-exposure prophylaxis among men in downtown Toronto, CanadaInt J STD AIDS2011221273874122174057
  • YoungILiJMcDaidLAwareness and willingness to use HIV pre-exposure prophylaxis amongst gay and bisexual men in Scotland: implications for biomedical HIV preventionPLoS One201385e6403823691143
  • WheelockAEisingerichABAnanworanichJAre Thai MSM willing to take PrEP for HIV prevention? An analysis of attitudes, preferences and acceptancePLoS One201381e5428823342121
  • YeLWeiSZouYHIV pre-exposure prophylaxis interest among female sex workers in Guangxi, ChinaPLoS One201491e8620024465956
  • SteinMThurmondPBaileyGWillingness to use HIV pre-exposure prophylaxis among opiate usersAIDS Behav20141891694170024752703
  • EisingerichABWheelockAGomezGBGarnettGPDybulMRPiotPKAttitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: a multinational studyPLoS One201271e2823822247757
  • WingoodGMDunkleKCampCRacial differences and correlates of potential adoption of preexposure prophylaxis: results of a national surveyJ Acquir Immune Defic Syndr201363Suppl 1S95S10123673895
  • FlashCLandovitzRGilerRMTwo years of Truvada for pre-exposure prophylaxis utilization in the USJ Int AIDS Soc2014174 Suppl 31973025397476
  • RoehrBFDA approves first drug to prevent HIV infectionBMJ2012345e487922807165
  • WhiteJMMimiagaMJKrakowerDSMayerKHEvolution of Massachusetts physician attitudes, knowledge, and experience regarding the use of antiretrovirals for HIV preventionAIDS Patient Care STDS201226739540522694239
  • SharmaMWiltonJSennHFowlerSTanDHPreparing for PrEP: perceptions and readiness of Canadian physicians for the implementation of HIV pre-exposure prophylaxisPLoS One201498e10528325133648
  • SchererMLDouglasNCChurnetBHSurvey of HIV care providers on management of HIV serodiscordant couples – assessment of attitudes, knowledge, and practicesAIDS Care201426111435143924878166
  • KarrisMYBeekmannSEMehtaSRAndersonCMPolgreenPMAre we prepped for preexposure prophylaxis (PrEP)? Provider opinions on the real-world use of PrEP in the United States and CanadaClin Infect Dis201458570471224319083
  • SachdevDDStojanovskiKLiuAYBuchbinderSPMacalinoGEIntentions to prescribe preexposure prophylaxis are associated with self-efficacy and normative beliefsClin Infect Dis201458121786178724729556
  • MimiagaMJWhiteJMKrakowerDSBielloKBMayerKHSuboptimal awareness and comprehension of published preexposure prophylaxis efficacy results among physicians in MassachusettsAIDS Care201426668469324116985
  • TripathiAOgbuanuCMongerMGibsonJJDuffusWAPreexposure prophylaxis for HIV infection: healthcare providers’ knowledge, perception, and willingness to adopt future implementation in the southern USSouth Med J2012105419920622475669
  • TellalianDMaznaviKBredeekUFHardyWDPre-exposure prophylaxis (PrEP) for HIV infection: results of a survey of HIV healthcare providers evaluating their knowledge, attitudes, and prescribing practicesAIDS Patient Care STDS2013271055355924053478
  • KrakowerDWareNMittyJAMaloneyKMayerKHHIV providers’ perceived barriers and facilitators to implementing pre-exposure prophylaxis in care settings: a qualitative studyAIDS Behav20141891712172124965676
  • BrunoCSaberiPPharmacists as providers of HIV pre-exposure prophylaxisInt J Clin Pharm201234680380623073703
  • HosekSGHIV pre-exposure prophylaxis diffusion and implementation issues in nonclinical settingsAm J Prev Med2013441 Suppl 2S129S13223253753
  • SennHWiltonJSharmaMFowlerSTanDHKnowledge of and opinions on HIV preexposure prophylaxis among front-line service providers at Canadian AIDS service organizationsAIDS Res Hum Retroviruses20132991183118923731254
  • NguyenVKBajosNDubois-ArberFO’MalleyJPirkleCMRemedicalizing an epidemic: from HIV treatment as prevention to HIV treatment is preventionAIDS201125329129320962615
  • KingHLKellerSBGiancolaMAPre-exposure prophylaxis accessibility research and evaluation (PrEPARE Study)AIDS Behav20141891722172525017425
  • LiuACohenSFollansbeeSEarly experiences implementing pre-exposure prophylaxis (PrEP) for HIV prevention in San FranciscoPLoS Med2014113e100161324595035
  • CohenSEVittinghoffEAndersonPLDoblecki-LewisSImplementation of PrEP in STD Clinics and a Community Health Center: High Uptake and Drug Levels among MSM in the Demo ProjectAbstract presented at: 21st Conference on Retroviruses and Opportunistic InfectionsMarch 3–6, 2014Boston, MA
  • WhethamJTaylorSCharlwoodLPre-exposure prophylaxis for conception (PrEP-C) as a risk reduction strategy in HIV-positive men and HIV-negative women in the UKAIDS Care201426333233623876052
  • VernazzaPLGrafISonnenberg-SchwanUGeitMMeurerAPreexposure prophylaxis and timed intercourse for HIV-discordant couples willing to conceive a childAIDS201125162005200821716070
  • AntonucciSDesaiMDollingDThe UK PROUD PrEP pilot study: a baseline analysisAbstract presented at: 20th International AIDS ConferenceJuly 20–25, 2014Melbourne, Australia
  • HeffronRCelumCMugoNHigh Initiation of PrEP and ART in a Demonstration Project among African HIV-discordant couplesAbstract presented at: 21st Conference on Retroviruses and Opportunistic InfectionsMarch 3–6, 2014Boston, MA
  • NdasePCelumCCampbellJSuccessful discontinuation of the placebo arm and provision of an effective HIV prevention product after a positive interim efficacy result: the partners PrEP study experienceJ Acquir Immune Defic Syndr201466220621224828268
  • GrantRMAndersonPLMcMahanViPrEx study teamUptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort studyLancet Infect Dis201414982082925065857
  • ChirwaLITaylorAWilliamsTEnrollment into open-label phase of TDF2 PrEP Study, Botswana, 2013Abstract presented at: 20th International AIDS ConferenceJuly 20–25, 2014Melbourne, Australia
  • DuranDTruvada whores?The Huffington Post12112012 Available from: http://www.huffingtonpost.com/david-duran/truvada-whores_b_2113588.htmlAccessed September 15, 2014
  • MyersJESepkowitzKAA pill for HIV prevention: déjà vu all over again?Clin Infect Dis201356111604161223408681
  • VermundSHVan LithLMHoltgraveDStrategic roles for health communication in combination HIV prevention and care programsJ Acquir Immune Defic Syndr201466Suppl 3S237S24025007259
  • MustanskiBRyanDTSanchezTSineathCMacapagalKSullivanPSEffects of messaging about multiple biomedical and behavioral HIV prevention methods on intentions to use among US MSM: results of an experimental messaging studyAIDS Behav20141891651166024907778
  • BaconOVittinghoffECohenSDoblecki-LewisSPrEP awareness in men who have sex with men (MSM) and transgender women (TGW) assessed for participation in the US PrEP demonstration projectAbstract presented at: 20th International AIDS ConferenceJuly 20–25, 2014Melbourne, Australia
  • GallagherTLinkLRamosMBottgerEAbergJDaskalakisDPerception of HIV risk and candidacy for pre-exposure prophylaxis among men who have sex with men testing for HIV at commercial sex venues in New York CityLGBT Health201413218224
  • KrakowerDMayerKHEngaging healthcare providers to implement HIV pre-exposure prophylaxisCurr Opin HIV AIDS20127659359923032736
  • ArnoldEAHazeltonPLaneTA qualitative study of provider thoughts on implementing pre-exposure prophylaxis (PrEP) in clinical settings to prevent HIV infectionPLoS One201277e4060322792384
  • CohenMSChenYQMcCauleyMHPTN 052 Study TeamPrevention of HIV-1 infection with early antiretroviral therapyN Engl J Med2011365649350521767103
  • RodgerABruunTCambianoVHIV transmission risk through condomless sex if HIV+ partner on suppressive ART: PARTNER studyAbstract presented at: 21st Conference on Retroviruses and Opportunistic InfectionsMarch 3–6, 2014Boston, MA
  • MarksGCrepazNJanssenRSEstimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USAAIDS200620101447145016791020
  • BrownAEGillONDelpechVCHIV treatment as prevention among men who have sex with men in the UK: is transmission controlled by universal access to HIV treatment and care?HIV Med201314956357023890150
  • ZablotskaIGrulichARisk assessment and eligibility for pre-exposure prophylaxis to prevent HIV infection among men who have sex with menAbstract presented at: 20th International AIDS ConferenceJuly 20–25, 2014Melbourne, Australia
  • SmithDKPalsSLHerbstJHShindeSCareyJWDevelopment of a clinical screening index predictive of incident HIV infection among men who have sex with men in the United StatesJ Acquir Immune Defic Syndr201260442142722487585
  • KahleEMHughesJPLingappaJRPartners in Prevention HSVHIV Transmission Study and the Partners PrEP Study TeamsAn empiric risk scoring tool for identifying high-risk heterosexual HIV-1-serodiscordant couples for targeted HIV-1 preventionJ Acquir Immune Defic Syndr201362333934723187945
  • BuchbinderSPGliddenDVLiuAYHIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trialLancet Infect Dis201414646847524613084
  • SolomonMMMayerKHGliddenDViPrEx Study TeamSyphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trialClin Infect Dis20145971020102624928295
  • AmicoKRStirrattMJAdherence to preexposure prophylaxis: current, emerging, and anticipated bases of evidenceClin Infect Dis201459Suppl 1S55S6024926036
  • van der StratenAStadlerJMontgomeryEWomen’s experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South AfricaPLoS One201492e8911824586534
  • HabererJEBaetenJMCampbellJAdherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East AfricaPLoS Med2013109e100151124058300
  • Medical Research Council Clinical Trials UnitPROUD Study Interim Analysis Finds Pre-exposure Prophylaxis (PrEP) is Highly Protective against HIV for Gay Men and Other Men Who have Sex with Men in the UKWiltshire, UKMedical Research Council, Clinical Trials Unit2014 Available from: http://www.proud.mrc.ac.uk/PDF/PROUD%20Statement%20161014.pdfAccessed December 23, 2014
  • McCormackSDunnDPragmatic Open-Label Randomised Trial of Preexposure Prophylaxis: The PROUD StudyAbstract presented at: 22nd Conference on Retroviruses and Opportunistic Infections (CROI)Feb 23–26, 2015Seattle, USA
  • PinesHAGorbachPMWeissRESexual risk trajectories among MSM in the United States: implications for pre-exposure prophylaxis deliveryJ Acquir Immune Defic Syndr201465557958624378726
  • MarcusJLBuiskerTHorvathTHelping our patients take HIV pre-exposure prophylaxis (PrEP): a systematic review of adherence interventionsHIV Med201415738539524580813
  • PsarosCHabererJEKatabiraEAn intervention to support HIV preexposure prophylaxis adherence in HIV-serodiscordant couples in UgandaJ Acquir Immune Defic Syndr201466552252924853311
  • R AmicoKMcMahanVGoicocheaPSupporting study product use and accuracy in self-report in the iPrEx study: next step counseling and neutral assessmentAIDS Behav20121651243125922460228
  • MansoorLEKarimQAWernerLImpact of an adherence intervention on the effectiveness of tenofovir gel in the CAPRISA 004 trialAIDS Behav201418584184824633717
  • MarcusJLGliddenDVMayerKHNo evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxisPLoS One2013812e8199724367497
  • MartinMVanichseniSSuntharasamaiPBangkok Tenofovir Study GroupRisk behaviors and risk factors for HIV infection among participants in the Bangkok tenofovir study, an HIV pre-exposure prophylaxis trial among people who inject drugsPLoS One201493e9280924667938
  • LiuAYVittinghoffEChillagKSexual risk behavior among HIV-uninfected men who have sex with men participating in a tenofovir preexposure prophylaxis randomized trial in the United StatesJ Acquir Immune Defic Syndr2013641879423481668
  • MugwanyaKKDonnellDCelumCPartners PrEP Study TeamSexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysisLancet Infect Dis201313121021102824139639
  • EatonLAHuedo-MedinaTBKalichmanSCMeta-analysis of single-session behavioral interventions to prevent sexually transmitted infections: implications for bundling prevention packagesAm J Public Health201210211e34e4422994247
  • JohnsonWDDiazRMFlandersWDBehavioral interventions to reduce risk for sexual transmission of HIV among men who have sex with menCochrane Database Syst Rev20083CD00123018646068
  • CelumCMorrowRADonnellDPartners PrEP Study TeamDaily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trialAnn Intern Med20141611111924979446
  • HeuftMMHoubaSMvan den BerkGEProtective effect of hepatitis B virus-active antiretroviral therapy against primary hepatitis B virus infectionAIDS2014287999100524685742
  • MarcusJLGliddenDVMcMahanVDaily oral emtricitabine/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with menPLoS One201493e9151324637511
  • TanDHGoddey-ErikefeBGoughKAYoongDNaccaratoMHartTHigh prevalence of syndemic health problems among patients using HIV post-exposure prophylaxis: implications for program deliveryAbstract presented at: 23rd Annual Canadian Association of HIV/AIDS Research Conference; 23rd Annual Canadian Association of HIV/AIDS Research ConferenceMay 1–4, 2014St John’s, NL
  • PoyntenIMJinFMaoLNonoccupational postexposure prophylaxis, subsequent risk behaviour and HIV incidence in a cohort of Australian homosexual menAIDS20092391119112619417578
  • KoesterKAmicoRLiuASex on PrEP: qualitative findings from the iPrEx open label extension (OLE) in the USAbstract presented at: 20th International AIDS ConferenceJuly 20–25, 2014Melbourne, Australia
  • Partners Demonstration Project [webpage on the Internet]University of Washington International Clinical Research Center2008 Available from: http://depts.washington.edu/uwicrc/research/studies/demo.htmlAccessed December 23, 2014
  • VicPrEP [homepage on the Internet]Victorian Pre-Exposure Prophylaxis Project Available from: http://vicprep.csrh.org/index.phpAccessed December 23, 2014